Pentoxifylline is a phosphodiesterase inhibitor that reduces TNF levels and proved promising in two clinical trials with adult and pediatric patients of CM based on increased survival and shorter coma duration (Di Perri et al., 1995; Das et al., 2003). Here, TNF is linked to cutaneous mastocytosis.